tiprankstipranks
Acorda Therapeutics: Bankruptcy Sale, Equity Cancellation, and Leadership Changes
Company Announcements

Acorda Therapeutics: Bankruptcy Sale, Equity Cancellation, and Leadership Changes

Don't Miss Our Christmas Offers:

Acorda Therapeutics (ACORQ) has shared an announcement.

Acorda Therapeutics, Inc. has finalized an asset sale to Merz Pharmaceuticals for $185 million, after filing for Chapter 11 bankruptcy. The company’s equity will be canceled, with no distributions to equity holders, as a Liquidation Plan takes effect. A Liquidating Trustee will manage the sale proceeds and handle the company’s dissolution, representing a significant shift in the company’s trajectory and a cautionary tale for investors in similar situations.

Learn more about ACORQ stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAcorda Therapeutics Commences Chapter 11 Proceedings
TipRanks Auto-Generated NewsdeskAcorda Therapeutics Announces Chapter 11 Proceedings
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App